1. Home
  2. CHRN vs ARQT Comparison

CHRN vs ARQT Comparison

Compare CHRN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ChronoScale Corporation Common Stock

CHRN

ChronoScale Corporation Common Stock

HOLD

Current Price

$15.28

Market Cap

2.9B

Sector

Industrials

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

SELL

Current Price

$28.53

Market Cap

3.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CHRN
ARQT
Founded
2026
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.2B
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
CHRN
ARQT
Price
$15.28
$28.53
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $38.38
AVG Volume (30 Days)
120.6K
★ 2.9M
Earning Date
10-14-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 92.67
88.79
EPS
N/A
★ 0.03
Revenue
N/A
★ $376,072,000.00
Revenue This Year
$84.77
$43.01
Revenue Next Year
$603.10
$27.70
P/E Ratio
★ N/A
$970.00
Revenue Growth
N/A
★ 91.34
52 Week Low
$12.62
$19.30
52 Week High
$30.00
$31.77

Technical Indicators

Market Signals
Indicator
CHRN
ARQT
Relative Strength Index (RSI) 34.10 62.77
Support Level N/A $24.91
Resistance Level $22.29 $30.30
Average True Range (ATR) 1.57 1.20
MACD -0.44 0.32
Stochastic Oscillator 30.01 84.07

Price Performance

Historical Comparison
CHRN
ARQT

About CHRN ChronoScale Corporation Common Stock

ChronoScale Holdings Corp is providing cloud services to customers at third-party colocation centers located in Colorado, Minnesota and Utah, such as artificial intelligence and machine learning developers, seeking to develop their products. It design, develop, and market exoskeleton and complementary products that augment human strength, endurance, and mobility. Its Cloud Business provides graphics processing unit (GPU) computing solutions that enable customers to execute critical workloads related to artificial intelligence (AI), machine learning (ML), rendering, and other High Performance Computing (HPC) tasks at scale in a capacity-constrained market. It has one operating segment Cloud Business.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: